NR

AYURCANN HOLDINGS CORP. PROVIDES CORPORATE UPDATE, AND GROWTH STRATEGY

Retrieved on: 
Thursday, August 10, 2023
Rationalization, CSE, NR, OTCQB, Fuego, FSE, Stock, H&S, Steam, SKU, Cannabis, Growth, Drug, Powder metallurgy

Top Company brands: Fuego, XPLOR and H&S, are consistent performers across the country with increased market share.

Key Points: 
  • Top Company brands: Fuego, XPLOR and H&S, are consistent performers across the country with increased market share.
  • Focused on top selling categories, using, and improving existing efficiencies to enhance production and market share while addressing SKU rationalization and price compression.
  • Ayurcann is proud to be debt free and have the ability to sustain its growth trajectory in the industry.
  • With the growth of our in-house brands, Fuego, H&S, XPLOR our products are being embraced by cannabis consumers.

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Tru, Glaucoma, Heart, Abstract, ARVO, Marketing, NR, Replay, NAD, GAAP, ChromaDex, Brain, History, Trial of the century, Net, EBITDA, Acquisition, Patient, Investment, Annual report, Investigative Ophthalmology & Visual Science, Webcast, Growth, Association for Research in Vision and Ophthalmology, Infant, Security (finance), Adjustment, Conference, WalletHub, Video game, Pharmaceutical industry, Communications satellite, Ophthalmology

ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023.
  • Net loss was $2.2 million or $(0.03) per share, an improvement of $4.2 million, or $0.06 per share, from the prior year quarter.
  • Adjusted EBITDA, a non-GAAP measure, was a positive $0.2 million, a $4.9 million improvement from the prior year quarter.
  • “This was another excellent quarter, delivering 21% year-over-year revenue growth, positive Adjusted EBITDA of $0.2 million and positive operating cash flows for the second consecutive quarter,” said ChromaDex Chief Executive Officer, Rob Fried.

ChromaDex Launches Tru Niagen® with iHerb, the World’s Number One Online Destination for Health and Wellness

Retrieved on: 
Tuesday, August 8, 2023
Online Retail, Retail, Health, General Health, Research, Science, Nobel Prize, Vitacost, Life, NR, House (brand), Ageing, NAD, ChromaDex, GNC, SVP, Family, Abrasive

ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destination for health and wellness, iHerb, as the newest retail partner to distribute Tru Niagen globally.

Key Points: 
  • ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world’s number one online destination for health and wellness, iHerb, as the newest retail partner to distribute Tru Niagen globally.
  • iHerb is on a mission to make health and wellness accessible to all offering the best brands in the industry and has established a strong international presence, with nearly 90% of sales generated outside of the United States.
  • iHerb has a global audience larger than Vitacost, VitaminShoppe, and GNC combined, proudly totaling 10 million active customers across more than 180 countries.
  • “NAD+ is essential for life, yet our levels decrease with age and when we are under physiological stress,” commented Rob Fried, CEO of ChromaDex.

Fibocom 5G R16-compliant Module FM160-EAU Achieved Telstra Certification, Closing the Digital Divide with Future-proof FWA Solution across Australia

Retrieved on: 
Thursday, August 3, 2023
Digital divide, Carrier aggregation, Communication, FWA, NBN, DL, NR, USB, Qualcomm, UL, Certification, ODU, Internet, 3GPP, Industrial, CPE, X62, Mobile phone, GNSS, Internet of things, Telstra

SHENZHEN, China, Aug. 3, 2023 /PRNewswire/ -- Fibocom (Stock code: 300638), a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, announced that the 3GPP Release 16 compliant module FM160-EAU has achieved the Telstra certification. The module has been tested and verified on Telstra's network to provide a high-performance 5G broadband service, driving the 5G adoption across industries such as FWA, security monitoring, and Industrial IoT in the regional market.

Key Points: 
  • Recently, Fibocom has achieved certification from Telstra, the leading mobile network service provider in Australia, with its SDX62-empowered module FM160-EAU tested on Telstra's 5G network, further verifying the capability of delivering superior and reliable connectivity service to local users.
  • The module has been tested and verified on Telstra's network to provide a high-performance 5G broadband service, driving the 5G adoption across industries such as FWA, security monitoring, and Industrial IoT in the regional market.
  • The 5G Sub-6GHz module FM160-EAU is designed to provide an optimal 5G user experience with enhanced coverage, boosted throughput, and increased bandwidth.
  • "With the implementation of 5G infrastructure in the regional market, we hope to deliver the resilient, fast and secure FM160-enabled 5G FWA solution to the Australian market in collaboration with Telstra."

Keysight Secures First Release 16 Power Saving Test Case Validations

Retrieved on: 
Monday, July 31, 2023
Technology, Telecommunications, Software, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Consumer Electronics, NR, GCF, DVT, Global Certification Forum, CAG, RRM, Radio, 3GPP, NYSE, RF, Medical device, Mobile phone, Keysight

Keysight Technologies, Inc. (NYSE: KEYS) gained approval for the industry’s first 5G New Radio (NR) Release 16 (Rel-16) power saving test cases for demodulation and radio resource management (RRM) in the n78 frequency band.

Key Points: 
  • Keysight Technologies, Inc. (NYSE: KEYS) gained approval for the industry’s first 5G New Radio (NR) Release 16 (Rel-16) power saving test cases for demodulation and radio resource management (RRM) in the n78 frequency band.
  • With the addition of these test cases available through the S8705A RF/RRM DVT and Conformance Toolset , Keysight extends its test case leadership by having the greatest number of new test case / band validations and activating the greatest number of new work items now available for certification testing.
  • In addition to securing the Release 16 demodulation and RRM validated test cases, we are working on the new power-saving test cases for Release 17.
  • These new validated test cases firmly cement Keysight’s leadership of having the best 5G NR test case coverage in the industry at 98%.”

NEWPARK RESOURCES ANNOUNCES SECOND QUARTER 2023 RESULTS CONFERENCE CALL AND WEBCAST DATE

Retrieved on: 
Wednesday, July 19, 2023
Newpark Resources, Newpark Comprehensive School, NYSE, NR

THE WOODLANDS, Texas, July 19, 2023 /PRNewswire/ -- Newpark Resources, Inc. (NYSE: NR) ("Newpark" or the "Company"), today announced that it will release second quarter 2023 results after the U.S. markets close on Tuesday, August 1, 2023.

Key Points: 
  • THE WOODLANDS, Texas, July 19, 2023 /PRNewswire/ -- Newpark Resources, Inc. (NYSE: NR) ("Newpark" or the "Company"), today announced that it will release second quarter 2023 results after the U.S. markets close on Tuesday, August 1, 2023.
  • A conference call will be held the following day on Wednesday, August 2, 2023 at 9:30 a.m.
  • ET to review the Company's financial results and conduct a question-and-answer session.
  • A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of the Company's website at https://investor.newpark.com/ .

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Retrieved on: 
Tuesday, July 18, 2023
Seniors, Biotechnology, Pharmaceutical, Optical, General Health, Health, Consumer, Clinical Trials, Glaucoma, Abstract, ARVO, Li Ka Shing Faculty of Medicine, NR, Eye, Control, NAD, UCL Institute of Ophthalmology, Research, ChromaDex, Trial of the century, School of Clinical Medicine, University of Cambridge, Medicine, Moorfields Eye Hospital, Patient, Peripheral vision, Randomness, School, Investigative Ophthalmology & Visual Science, Optic nerve, Association for Research in Vision and Ophthalmology, Regulatory affairs, Medical device, Medical imaging, Ophthalmology

Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.

Key Points: 
  • Together, the promising results from these abstracts suggest that glaucoma patients have lower cellular NAD+ levels and thus replenishing NAD+ levels with a precursor, such as nicotinamide riboside (NR), may be a potential therapeutic strategy.
  • Dr. Garway-Heath’s abstract titled “ Primary open angle glaucoma patients have lower systemic mitochondrial function, associated with lower systemic nicotinamide adenine dinucleotide (NAD) levels, compared to Controls ” observed significantly lower cellular NAD+ levels and impaired mitochondrial function in patients with primary open-angle glaucoma (POAG).
  • Further, higher NAD+ levels were strongly associated with higher mitochondrial function parameters, suggesting increased NAD+ levels are associated with improved energy production and cellular activity.
  • POAG is a condition where pressure builds inside the eye, causing damage to the optic nerve and gradual vision loss.

enCore Energy Reports 19.9% Ownership of Nuclear Fuels Inc.

Retrieved on: 
Monday, July 10, 2023
NF, CSE, NR, Disclosure, Encore, Acquisition, National instrument, Environmental Defense v. Duke Energy Corp., Fuel pump, News, NYSE, Uranium mining, Security (finance), EU

DALLAS, July 10, 2023 /PRNewswire/ - enCore Energy Corp. ("enCore" or the "Company") (NYSE American: EU) (TSXV: EU) announced today that the Company has received 9,263,800 shares of Nuclear Fuels Inc. (CSE: NF) (formerly Uravan Minerals Inc.) in exchange for shares of a private BC company (also named Nuclear Fuels) which held uranium projects in Wyoming and Arizona.

Key Points: 
  • DALLAS, July 10, 2023 /PRNewswire/ - enCore Energy Corp. ("enCore" or the "Company") (NYSE American: EU) (TSXV: EU) announced today that the Company has received 9,263,800 shares of Nuclear Fuels Inc. (CSE: NF) (formerly Uravan Minerals Inc.) in exchange for shares of a private BC company (also named Nuclear Fuels) which held uranium projects in Wyoming and Arizona.
  • ( enCore NR dated Nov 3, 2022 ).
  • Immediately prior to the acquisition, enCore held 64,000 post-consolidated common shares of Nuclear Fuels Inc. (CSE:NF).
  • A copy of the report may also be obtained by contacting William M. Sheriff, Executive Chairman, 361-239-5449, or at [email protected] .

Fibocom Boosts the Mobile Broadband Market by Introducing Pioneering 5G FWA Solution Embedded with FG190 and FG180 5G Modules at MWC Shanghai 2023

Retrieved on: 
Thursday, June 29, 2023
MLO, High-pass filter, Communication, A55, IEEE 802.11be, FWA, NR, PCI Express, Software design, Internet, X75, Hospital, LGA, OpenWrt, 3GPP, CPE, Printed circuit board, Mobile phone, Mobile World Congress

SHANGHAI, June 29, 2023 /PRNewswire/ -- Fibocom, a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, introduces the pioneering 5G FWA solution based on the latest generation 5G modules FG190 and FG180 at MWC Shanghai 2023. The solution offers a wide range of flexible configurations and multiple enhancements to CPE and mobile hot-spot customers, significantly reducing the complexity to deploy advanced 5G solutions and accelerate the time to market.

Key Points: 
  • SHANGHAI, June 29, 2023 /PRNewswire/ -- Fibocom, a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, introduces the pioneering 5G FWA solution based on the latest generation 5G modules FG190 and FG180 at MWC Shanghai 2023.
  • The cutting-edge 5G FWA solution specialized in CPE and mobile hot-spot use cases, embedded with Fibocom's latest generation 5G Sub-6GHz and mmWave modules FG190 and FG180.
  • In software design, Fibocom's cutting-edge 5G FWA solution embedded with FG190 and FG180 is loaded with OpenWRT, which allows maximum customization for CPE and mobile hot-spot customers.
  • Welcome to visit Fibocom and get to know more about the newly launched 5G FWA solution at stand #B80 in Hall N1 at MWC Shanghai 2023.

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

Retrieved on: 
Friday, June 16, 2023
Health, Hospitals, Other Health, General Health, Pharmaceutical, Vitamins, Supplements, Biotechnology, University of Helsinki, Science, Human, Cell Metabolism, University, PD, Heart failure, Metabolism, CERP, Science Advances, NR, Placebo, LVEF, Spinal cord, Research fellow, Clinical trial, Ageing, NAD, University of Oslo, Philip Morris External Research Program, ChromaDex, Research, Brain, Inflammation, Affiliation, Mitochondrion, DSM-IV codes, University of Washington School of Medicine, Trial of the century, Associate, Haukeland University Hospital, University of Bergen, City, Publication, Parkinson's disease, Patient, Division, Heart, University of Copenhagen Faculty of Health and Medical Sciences, University of Oulu, Diabetes, Safety, Copenhagen, Dietary supplement, Pharmaceutical industry, Medical device, Nicotinamide riboside, Cardiology

On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).

Key Points: 
  • On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th anniversary of its award-winning ChromaDex External Research Program (CERP™).
  • On behalf of the ChromaDex family, we are thrilled to commemorate our ChromaDex External Research Program as it celebrates a decade of setting the industry standard for excellence in collaborative research,” said Rob Fried, the CEO of ChromaDex.
  • This approach fosters great trust in the research, as often there is skepticism around industry-funded research in the dietary supplement industry.
  • Today, this unique, industry-leading program has research agreements with over 200 institutions in 31 countries, representing over $95 million in estimated total research value.